- Home
- MBIN vs DYN Comparison
MBIN vs DYN Comparison
Compare MBIN & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBIN | DYN |
|---|---|---|
| Founded | 1990 | 1984 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MBIN | DYN |
|---|---|---|
| Price | $49.52 | $15.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 17 |
| Target Price | ★ $64.50 | $37.20 |
| AVG Volume (30 Days) | 132.5K | ★ 3.2M |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.73 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.93 | N/A |
| Revenue Next Year | $6.80 | N/A |
| P/E Ratio | $18.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.37 | $12.43 |
| 52 Week High | $56.87 | $27.31 |
Technical Indicators
Market Signals| Indicator | MBIN | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 28.16 | 23.85 |
| Support Level | $45.39 | $14.34 |
| Resistance Level | $51.01 | $19.54 |
| Average True Range (ATR) | 1.20 | 0.76 |
| MACD | -0.40 | 0.02 |
| Stochastic Oscillator | 3.58 | 13.09 |
Price Performance
Historical ComparisonAbout MBIN Merchants Bancorp
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.